AMYRIS, INC. Form 8-K September 17, 2012

	UNITED ST SECURITIES AND EXCHA WASHINGTON,	ANGE COMMISSION	
	FORM 8	3-K	
	Current Report Pursuant to of the Securities Excha		
	September 14 Date of Report (Date of ear		
	Amyris, I (Exact name of Registrant as		
Delaware (State or other jurisdiction of incorporation)	0001-34885 (Commission file number)	55-0856121 (I.R.S. Employer Identification No.)	
•		94608 p Code)	
(510) 450-0761 (Registrant's telephone numbe	r, including area code)		
(Former name or former addre	ss, if changed since last report.)		
	ow if the Form 8-K filing is interfollowing provisions (see Gener	ended to simultaneously satisfy the filing obligation ral Instruction A.2 below):	ns of
Soliciting mater Pre-commencement comm	ial pursuant to Rule 14a-12 unde unications pursuant to Rule 14d-	under the Securities Act (17 CFR 230.425) ter the Exchange Act (17 CFR 240.14a-12) -2(b) under the Exchange Act (17 CFR 240.14d-2e-4(c) under the Exchange Act (17 CFR 240.13e-4e-4)	

## Item 1.01. Entry into a Material Definitive Agreement.

On September 14, 2012, Amyris, Inc. (the "Company") sold and issued a 1.5% Senior Unsecured Convertible Note Due 2017 to Total Gas & Power USA, SAS ("Total") in the face amount of \$15.0 million (the "Note"). The sale was completed under that certain Securities Purchase Agreement, dated as of July 30, 2012 (the "Purchase Agreement"), by and between the Company and Total. The description of the Purchase Agreement and related agreements with Total set forth in Item 1.01 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on July 31, 2012 (the "Previous Report") is incorporated herein by reference.

#### Background

The Purchase Agreement contemplates the sale of an aggregate of \$105 million in Notes (including the Note) as follows:

- As part of an initial closing under the Purchase Agreement (which initial closing was completed in two installments), (i) on July 30, 2012, the Company sold an initial 1.5% Senior Unsecured Convertible Note Due 2017 to Total in the face amount of \$38.3 million (such note, collectively with the Note and additional notes in the same form to be sold under the Purchase Agreement in the future, the "Notes") for \$38.3 million in proceeds, including \$15 million in new funds and repayment by the Company of \$23.3 million in previously-provided diesel research and development funding by Total, and (ii) on September 14, 2012, the Company sold the Note for \$15.0 million in new funds from Total.
- The Purchase Agreement provides that additional Notes may be sold in subsequent closings in July 2013 (for cash proceeds to the Company of \$30 million) and July 2014 (for cash proceeds to the Company of \$21.7 million, which would be settled in an initial installment of \$10.85 million payable at such closing and a second installment of \$10.85 million payable in January 2015).

Each of the closings under the Purchase Agreement is subject to customary closing conditions such as receipt of requisite approvals, good standing of the Company and accuracy of representations and warranties. In addition, Total's obligations with respect to each subsequent closing are subject to a condition that Total has not made a No-Go decision (as defined below) prior to certain notice deadlines. The subsequent installments for settlement of the initial and third closings described above are subject to conditions that certain representations and warranties of the Company continue to be true as of the date of such installment payment.

#### Terms of Note

The Note has a March 1, 2017 maturity date and a conversion price equal to \$7.0682 per share of Company common stock (the "Common Stock"). The Note becomes convertible into Common Stock or payable by the Company to Total depending on various conditions, including whether or not Total makes certain "Go" or "No-Go" decisions with respect to its participation in a Biofene® (Company farnesene)-based diesel collaboration between the Company and Total, descriptions of which are provided in the Previous Report. Specifically, the Note becomes convertible into Common Stock (i) within 10 trading days prior to maturity (if it is not canceled prior to its maturity date based on a Go decision), (ii) on a change of control of the Company, (iii) if Total is no longer the largest stockholder of the Company following a No-Go decision (subject to a six-month lock-up with respect to any shares of Common Stock, issued upon conversion), and (iv) on a default by the Company. If Total makes a final Go decision, then the Note will be exchanged by Total for equity interests in the fuels joint venture contemplated by the collaboration, after which the Note will not be convertible and any obligation to pay principal or interest on the Note will be extinguished. If Total makes a No-Go decision, outstanding Notes will remain outstanding and become payable at maturity. The Note bears interest of 1.5% per year (with a default rate of 2.5%), accruing from date of funding and payable at maturity or on

## Edgar Filing: AMYRIS, INC. - Form 8-K

conversion or a change of control where Total exercises a right to put the Note to the Company, as described in the Previous Report. Accrued interest is canceled if the Note is canceled based on a Go decision.

The conversion price of the Note is subject to adjustment for proportional adjustments to outstanding Common Stock and under anti-dilution provisions in case of certain dividends and distributions. Total has a right to require repayment of 101% of the principal amount of the Note in the event of a change of control of the Company and the Note provides for payment of unpaid interest on conversion following such a change of control if Total does not require such repayment. The Purchase Agreement and Note include covenants regarding payment of interest, maintenance of the Company's listing status, limitations on debt, maintenance of corporate existence, and filing of SEC reports. The Note includes standard events of default resulting in acceleration of indebtedness, including failure to pay, bankruptcy and insolvency, cross-defaults, and breaches of the covenants in the Purchase Agreement and the Note (and other notes issued under the Purchase Agreement), with added default interest rates and associated cure periods applicable to the covenant regarding SEC reporting.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of Registrant.

The information contained in Item 1.01 above is incorporated herein by reference.

Item 3.02. Unregistered Sales of Equity Securities

The information contained in Item 1.01 above is incorporated herein by reference.

The sale and issuance of the Note as disclosed in Item 1.01 of this Current Report on Form 8-K has been determined to be exempt from registration under the Act in reliance on Section 4(2) of the Act and Rule 506 of Regulation D promulgated under the Act.

# Edgar Filing: AMYRIS, INC. - Form 8-K

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amyris, Inc.

Date: September 17, 2012 By: /s/ Gary Loeb

SVP and General Counsel